Follows people with heart rhythm problems treated with catheter ablation
Records real-world results of catheter ablation for atrial fibrillation and ventricular arrhythmia in adults.
Plain-language title generated from the registry record
Registry title: Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Key facts
- Where
- Edmonton, Kitchener, Montreal, and Newmarket, CanadaSee the 4 sites
Where in Canada
- Alberta HealthEdmonton, CanadaTaking people
- Waterloo Wellington Cardiovascular Research InstituteKitchener, CanadaTaking people
- Montreal Heart InstituteMontreal, CanadaTaking people
- Southlake Regional Health CentreNewmarket, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Heart Rhythm Clinical and Research Solutions, LLC
- Trial code
- NCT04088071
- Record updated
- 22 September 2026
- Original description
The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.Read full original descriptionShow less
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Symptomatic Using Novel CARTO Technologies: REAL Registry
The primary purpose of this Registry is to assess procedural safety and long-term effectiveness of catheter ablations in the treatment of subjects with PAF, PsAF, and VA. The Registry will utilize real world clinical data obtained from the use of commercially available CARTO™ technologies under the authority of a health care practitioner within a legitimate practitioner-subject relationship. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term effectiveness of catheter ablation with novel technologies for arrhythmia patients.
Inclusion: Symptomatic PAF (AF episode terminate spontaneously within 7 days) or PsAF (AF sustained beyond 7 days, but less than 365 days) subjects who, in the opinion of the investigator, are candidates for catheter ablation; >18 years of age; Will be treated with Biosense Webster Inc. ablation technologies; All AF ablations performed with BWI catheters are included. This includes repeat ablations where the index procedure was performed with a non-BWI catheter; Able and willing to participate in baseline and follow up evaluations; Willing and able to provide informed consent, if applicable; Documented ventricular arrhythmia appropriate for catheter ablation; >18 years of age; Will be treated with Biosense Webster Inc. ablation technologies; Able and willing to participate in baseline and follow up evaluations; Willing and able to provide informed consent, if applicable.
Exclusion: Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan; Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan; Long-standing persistent AF (AF greater than one year); In the opinion of the investigator, any known contraindication to an ablation procedure; CORE VA Cohort; In the opinion of the investigator, any known contraindication to an ablation procedure.
REAL AF Cohort.